Alessandro Maselli, Catalent CEO (Adrien Villez for Endpoints News)
November 15, 2023 11:31 AM ESTUpdated November 16, 10:31 AM
Manufacturing

Is the worst over? Catal­ent touts GLP-1 and gene ther­a­py busi­ness as it sticks to fi­nan­cial guid­ance

Anna Brown

News Reporter

Catal­ent’s fi­nan­cial health ap­pears to be on the mend thanks to spe­cif­ic seg­ments of its man­u­fac­tur­ing busi­ness, but the CD­MO still has a long road …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

Im­mat­ics heads to Phase 3 with melanoma cell ther­a­py, seeks to raise $150M

A service from the Financial Times